









Markets
/
Stocks
/
nasdaq-ntrbw
/

Nutriband Inc

NTRBW

View Detailed Chart

1.700

+0.030+1.80%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

--Market Cap

--P/E TTM



Nutriband Inc

1.700

+0.030+1.80%

Overview Company Financials

Financials

Intraday

30m

Today

+1.80%

5 Days

-27.40%

1 Month

-46.88%

6 Months

-4.49%

Year to Date

+21.43%

1 Year

+18.88%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(3)

Neutral(4)

Buy(5)

Indicators

Sell(1)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.139

Neutral

RSI(14)

49.607

Neutral

STOCH(KDJ)(9,3,3)

68.274

Neutral

ATR(14)

0.890

High Vlolatility

CCI(14)

6.147

Neutral

Williams %R

39.929

Buy

TRIX(12,20)

-0.355

Sell

StochRSI(14)

85.574

Overbought

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.460

Buy

MA10

1.800

Sell

MA20

1.977

Sell

MA50

1.633

Buy

MA100

1.413

Buy

MA200

1.495

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Ticker SymbolNTRBW

CompanyNutriband Inc

CEOMr. Gareth Sheridan

Websitehttps://nutriband.com/